CANADIAN TELERADIOLOGY SERVICES

Management's Discussion and Analysis

For the Three and Nine Months Ended September 30, 2020

(Expressed in Canadian Dollars)

304-85 Scardale Rd., Toronto, ON, Canada M3B 2R2, Telephone: (877) 722-6965, Fax: (416) 900-0957 www.ctsrad.com.

OVERVIEW

Canadian Teleradiology Services, Inc. ("CTS" or the "Company") is incorporated federally under the Canada Business Corporations Act. The Company's principal business activity is providing Teleradiology services (remote radiology) to smaller urban and rural hospitals, using licensed IT platforms and hosted servers.

Teleradiology is the process of providing remote off site reading of radiology scans such as CT, MRI, US and X-ray. Hospital staff scan their emergency room patients, then page the CTS radiologist on call, who can then remotely view, via secured server, the images and diagnose the patient and provide a report back to the hospital.

Teleradiology is the next level of patient care that assists small urban and rural hospitals to connect with 24/7 care, ensuring their communities receive the same care that large urban hospitals receive.

The Company's registered head office is 304-85 Scardale Rd., Toronto, ON, Canada M3B 2R2. The Company's website is www.ctsrad.com.

The following Management's Discussion and Analysis of CTS should be read in conjunction with the Company's Unaudited Condensed Interim Financial Statements for the three and nine months ended September 30, 2020 and notes thereto. This Management's Discussion and Analysis is dated December 16, 2020 and has been approved by the Board of Directors of the Company.

The Company's Unaudited Condensed Interim Financial Statements for the three and nine months ended September 30, 2020, were prepared using the same accounting policies and methods of computation as those described in our Audited Financial Statements for the year ended December 31, 2019. Any subsequent changes to IFRS that are given effect in the Company's annual financial statements for the year ending December 31, 2020 could result in restatement of the Unaudited Condensed Interim Financial Statements. The Unaudited Condensed Interim Financial Statements should be read in conjunction with the Audited Financial Statements for the year ended December 31, 2019. All amounts herein are presented in Canadian dollars, unless otherwise noted.

The Unaudited Condensed Interim Financial Statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and interpretations issued by the IFRS Interpretations Committee ("IFRIC"). The Unaudited Interim Condensed Consolidated Financial Statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by the IASB and interpretations issued by IFRIC.

FORWARD LOOKING STATEMENTS

This MD&A contains certain statements that may constitute "forward-looking statements". Forward-looking statements include but are not limited to, statements regarding future anticipated business developments and the timing thereof, regulatory compliance, sufficiency of working capital, and business and financing plans. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of material risks and uncertainties. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or which by their nature refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, the Company's ability to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies.

The Company has based the forward-looking statements largely on the Company's current expectations, estimates, assumptions, and projections about future events and financial and other trends that the Company believes, as of the date of such statements, may affect its business, financial condition and results of operations. Such expectations, estimates, assumptions, and projections, many of which are beyond the Company's control, include, but are not limited to: management's expectations regarding the future business, objectives and, operations of the Company; the Company's anticipated cash needs and the need for additional financing; the Company's ability to successfully complete future financings; the acceptance by the marketplace of new technologies and solutions; the Company's expectations regarding its competitive position; the Company's expectations regarding regulatory developments and the impact of the regulatory environment in which the Company operates; the Company's ability to attract and retain qualified management personnel and key employees; and anticipated trends and challenges in the Company's business and the markets in which it operates. Assumptions underlying the Company's working capital requirements are based on management's experience with other public companies. Forward-looking statements pertaining to the Company's need for and ability to raise capital in the future are based on the projected costs of operating and management's experience with raising funds in current market circumstances. Forward-looking statements regarding treatment by governmental authorities assumes no material change in regulations, policies, or the application of the same by such authorities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made, and readers are advised to consider such forward-looking statements with the risks set forth.

OVERALL PERFORMANCE

For the nine months ended September 30, 2020, total revenue was higher by $92,822 to $4,016,402, compared to total revenue of $3,923,580 for the nine months ended September 30, 2019. The primary increase in revenue during the current period was attributed to the increased utilization of the Company's teleradiology services to client hospitals and clinics as a result of an increase in patient volume.

Total cost of sales during the nine months ended September 30, 2020, including reading fees, medical images archiving, internet connectivity and, radiologists and medical director expenses were $3,214,729 compared to $3,158,069 for the same nine month period in 2019. Higher cost of sales experienced during the nine month period in 2020, was primarily a result of increased reading fees as hospitals and clinics requiring the Company's services experienced an increase in patient volumes.

As a result of the above, during the nine month period ending September 30, 2020, gross profit increased by $36,162 to $801,673 versus gross profit of $765,511 for the nine month period in 2019.

Total expenses for the nine months ended September 30, 2020, were $679,479, higher by $70,159 when compared to total expenses of $609,320 for the nine months ended September 30, 2019. The primary factors relating to the increase in total expenses during the nine month period in 2020 were an increase in professional fees of $133,537, an increase in salaries and wages of $80,594, an increase of $33,334 in general and administrative costs and an increase of $32,261 in royalty costs. These increases experienced in the current period in 2020 were partially offset by a decrease in management fees of $156,582.

As a result of the above factors, the Company recorded a net income and comprehensive income for the nine months ended September 30, 2020, of $122,194 down by $33,997 as compared to a net income and comprehensive income of $156,191 for the nine months ended September 30, 2019. The income per share-basic and diluted for the nine months ended September 30, 2020 was $764 versus income per share-basic and diluted of $976 for the comparable nine month period in 2019.

On December 7, 2020, the Company and Good2Go2 Corp. a Capital Pool Corporation ("Good2Go2") closed its business combination as the "Qualifying Transaction" of Good2Go2 (as such term is defined within the meaning of Policy 2.4 - Capital Pool Companies of the TSX Venture Exchange (the "Exchange")).

Pursuant to the terms of the Business Combination Agreement dated effective July 15, 2020 and subsequent amending agreements entered among the Company, Good2Go2 and 12199483 Canada Inc. ("Subco"), a wholly-owned subsidiary of Good2Go2, CTS and Subco amalgamated under the *Canada Business Corporations Act* on December 7, 2020. Immediately prior to the closing of the Qualifying Transaction, Good2Go2 consolidated its common shares on a 1.8-for-one basis (the "Consolidation") resulting in 3,027,778 post-Consolidation shares and changed its name to Leveljump Healthcare Corp.

The common shares of Leveljump Healthcare Corp. resumed trading on the Exchange as a Tier 1 technology issuer on December 14, 2020 (the "Listing Date") under the new name "Leveljump Healthcare Corp.", with the trading symbol "JUMP" (see Subsequent Events).

TERMINATION OF FOGCHAIN TRANSACTION

On December 17th, 2019, the Company and its shareholders' entered into a Securities Exchange Agreement with FogChain Corp. ("FogChain") whereby FogChain would acquire all the issued and outstanding shares of the Company in exchange for shares of FogChain. The Securities Exchange Agreement was subsequently terminated effective June 22, 2020.

FINANCIAL INSTRUMENT RISK EXPOSURES AND MANAGEMENT

Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values. Unless otherwise disclosed their carrying values approximate their fair values due to the short-term nature of these instruments.

The Company's major financial risk factors and their impact on the financial statement are summarized below:

Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The Company's cash and accounts receivable are exposed to credit risk. CTS' cash is held with major Canadian-based financial institutions as such management believes that the associated credit risk is remote.

Accounts receivables represents revenue earned from services rendered to hospitals. The Company has adopted a credit policy under which each new customer is analyzed individually for creditworthiness before the Company's standard payment terms and conditions are offered.

The Company's trade receivables are concentrated among customers in the healthcare industry, which may be affected by adverse government policy impacting that industry. As at September 30, 2020 and December 31, 2019, three customers accounted for greater than 64% and 84% of the Company's trade receivable balance, respectively. There have been no changes to this risk exposure from 2019.

As at September 30, 2020 and December 31, 2019, the Company's maximum exposure to credit risk was as follows:

	September 30, 2020 ($)	December 31, 2019 ($)
Cash	10,357	-
Accounts receivable	550,696	515,919
Prepaid expenses and deposits	23,003	7,450
Due from Parent Company	40,269	92,496
Total	624,325	615,865

Liquidity risk

Liquidity risk is the risk that the Company cannot meet a demand for cash or fund its obligations as they become due. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities as they become due. The Company is expanding and in order to meet its short and longer-term working capital requirements, the Company will attempt, if necessary, to secure further financing to ensure that those obligations are properly discharged. Operationally, the Company manages its liquidity by continuously monitoring forecasted and actual gross profit, expenses, and cash flows from operations. There have been no changes to this risk exposure from 2019.

The following tables illustrate the contractual maturities of financial liabilities for the periods set out:

September 30, 2020	**Payments Due by Period $**				
	Total	Less than 1 year	1-3 years	4-5 years	After 5 years
Accounts payable and accrued liabilities	1,217,241	1,217,241	-	-	-
Lease liabilities	68,570	31,540	37,030	-	-
Due to director	50,655	50,655	-	-	-
Long-term debt	50,543	50,543	-	-	-
Loan payable	25,000	25,000	-	-	-
CEBA loan	40,000	-	40,000	-	-
TOTAL	1,452,009	1,374,979	77,030	-	-

December 31, 2019	**Payments Due by Period $**				
	Total	Less than 1 year	1-3 years	4-5 years	After 5 years
Bank overdraft	2,103	2,103	-	-	-
Accounts payable and accrued liabilities	1,170,874	1,170,874	-	-	-
Lease liabilities	88,249	27,552	60,697	-	-
Due to director	64,090	64,090	-	-	-
Long-term debt	98,995	98,995	-	-	-
TOTAL	1,424,311	1,363,614	60,697	-	-

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates. There have been no changes to this risk exposure from 2019.

Interest rate risk

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company is exposed to interest rate risk arising from fluctuations in the bank's prime rate related to its term loans. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities such as entering into fixed interest rate contracts. There have been no changes to this risk exposure from 2019.

Capital Management

The Company defines capital as total shareholders' equity and long-term debt. The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the growth and development of its operations and bring new products to market and to ensure it continues as a going concern. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company will continue to assess new opportunities and seek to acquire an interest in growth situations if it feels there is sufficient economic potential and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the nine months ended September 30, 2020. The Company is not subject to externally imposed capital requirements.

Covid-19

In March 2020, the World Health Organization declared a global pandemic related to the virus known as COVID-19. The expected impacts on global commerce are anticipated to be far reaching. To date there have been significant wide-spread stock market declines and the movement of people and goods has become restricted. As the Company has no material operating income or cash flows, it will be reliant on additional financing to fund ongoing operations and future acquisitions. An extended disruption may affect the Company's ability to obtain additional financing. The impact on the economy and the Company is not yet determinable; however, the Company's financial position, results of operations and cash flows in the current period have been impacted as patient volume has decreased resulting in decreased revenues for the Company. The Company's financial position, results of operations and cash flows in future periods may be materially affected. In particular, there may be heightened risk of liquidity or going concern uncertainty.

RESULTS OF OPERATIONS

	Three Months Ended September 30		Nine Months Ended September 30	
	2020 ($)	**2019 ($)**	**2020 ($)**	**2019 ($)**
Total revenue	1,518,375	1,371,537	4,016,4029	3,923,560
Gross profit	286,208	263,944	801,673	765,511
Net income and comprehensive income	42,151	74,111	122,194	156,191
Income per share–basic and diluted	263	666	764	976

REVENUES

Teleradiology

For the three months ended September 30, 2020, the Company's teleradiology revenue was $1,498,626 representing an increase of $162,411 compared to teleradiology revenue of $1,336,215 for the three months ended September 30, 2019. The primary increase in revenue during the current period was attributed to the increased utilization of the Company's teleradiology services to client hospitals and clinics as a result of increased patient volume.

For the nine months ended September 30, 2020, the Company's teleradiology revenue was $3,903,277 representing an increase of $90,304 compared to teleradiology revenue of $3,812,973 for the nine months ended September 30, 2019. The primary increase in revenue during the current nine month period was attributed to the increased utilization of the Company's teleradiology services to client hospitals and clinics as a result of increased patient volume.

Admin and Sublease and Other

For the three months ended September 30, 2020, the Company's admin and sublease and other revenue was lower by $15,583 to $19,749 versus admin and sublease revenue of $35,332 for the three months ended September 30, 2019.

For the nine months ended September 30, 2020, the Company's admin and sublease and other revenue increased slightly by $2,518 to $113,125 versus admin and sublease revenue of $110,607 for the nine months ended September 30, 2019.

The decrease in admin and sublease and other revenue for the three month period in 2020 was related to a decrease in sublease income.

TOTAL REVENUE

Total revenue for the three months ended September 30, 2020, was up $146,838 to $1,518,375 compared to total revenue of $1,371,537 for the three months ended September 30, 2019.

Total revenue for the nine months ended September 30, 2020, was up by $92,822 to $4,016,402 compared to total revenue of $3,923,580 for the nine months ended September 30, 2019.

The increase in total revenue for the three and nine month periods in fiscal 2020, is primarily a result of the increased utilization of the Company's teleradiology services to client hospitals and clinics as a result of increased patient volume.

COST OF SALES

Reading Fees
For the three months ended September 30, 2020, the Company's reading fees totaled $1,198,901 higher by $124,341 compared to reading fees of $1,074,560 for the three months ended September 30, 2019.

For the nine months ended September 30, 2020, the Company's reading fees totaled $3,121,658, higher by $63,871 compared to reading fees of $3,057,787 for the nine months ended September 30, 2019.

The increase in reading fees recorded during the current periods in fiscal 2020, was related to the increased utilization of the Company's teleradiology services to client hospitals and clinics as a result of increased patient volume.

Medical Images Archiving
Medical images archiving costs for the three months ended September 30, 2020, were $17,916 which were relatively consistent when compared to medical images archiving costs of $17,493 for the previous three months ended September 30, 2019.

Medical images archiving costs for the nine months ended September 30, 2020, were $47,981 which were down by $4,694 when compared to medical images archiving costs of $52,675 for the previous nine months ended September 30, 2019. The decrease in medical images archiving costs during the nine month period in 2020, was related to lower storage costs.

Internet Connectivity
For the three months ended September 30, 2020, the Company's internet connectivity costs were lower by $2,340 to $3,000 compared to $5,340 for the three months ended September 30, 2019.

For the nine months ended September 30, 2020, the Company's internet connectivity costs were lower by $6,007 to $10,050 compared to $16,057 for the nine months ended September 30, 2019.

The reduced internet connectivity costs experienced during the three and nine month periods in fiscal 2020 was a result of the Company negotiating lower pricing with its supplier.

Radiologists and Medical Director Expenses
For the three months ended September 30, 2020, the Company incurred radiologists and medical director expenses of $12,350 which was higher by $2,150 compared to $10,200 for the same three month period ended September 30, 2019.

For the nine months ended September 30, 2020, the Company incurred radiologists and medical director expenses of $35,040 which was higher by $3,490 compared to $31,550 for the same nine month period ended September 30, 2019.

The increase in radiologists and medical director expenses recorded during the three and nine month periods in fiscal 2020 was a result of increased patient volume.

TOTAL COST OF SALES

Total cost of sales during the current three month period ended September 30, 2020, including reading fees, medical images archiving, internet connectivity and radiologists and medical director expenses were $1,232,167 compared to $1,107,593 for the three months ended September 30, 2019.

Total cost of sales during the current nine month period ended September 30, 2020, including reading fees, medical images archiving, internet connectivity and radiologists and medical director expenses were $3,214,729 compared to $3,158,069 for the nine months ended September 30, 2019.

Higher total cost of sales experienced during the current three and nine month periods ended September 30, 2020, was primarily attributed to the increase in reading fees and increased radiologists and medical director expenses both related to increased patient volume.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross profit increased by $22,264 to $286,208 during the three month period ending September 30, 2020, versus gross profit of $263,944 for the same three month period ended September 30, 2019.

For the nine months ended September 30, 2020, the Company's gross profit increased by $36,162 to $801,673 during the nine month period ending September 30, 2020, compared to a gross profit of $765,511 for the same nine month period ended September 30, 2019.

EXPENSES

Salaries and Wages

For the three months ended September 30, 2020, the Company recorded salaries and wages of $92,337 which were relatively consistent when compared to salaries and wages of $93,799 for the three months ended September 30, 2019.

For the nine months ended September 30, 2020, the Company recorded salaries and wages of $280,187 compared to salaries and wages of $199,593 for the nine months ended September 30, 2019.

The increase of $80,594 in salaries recorded during the nine month period in fiscal 2020, was a result of the reclassification of the salaries of the Company's Chief Executive Officer and its Chief Financial Officer as well as the addition of administrative personnel.

Royalty Expense

Royalty expense for the three months ended September 30, 2020, was $34,096 compared to $31,893 for the three months ended September 30, 2019.

Royalty expense for the nine months ended September 30, 2020, was $93,349 compared to $61,088 for the nine months ended September 30, 2019. For the first quarter of 2019, the Company paid approximately $36,817 in royalty expense that was included in management fees.

The Company was party to an Amended and Restated Secured Royalty Purchase Agreement and as such pays a gross monthly sales royalty based on of 2.5% of its revenues or $6,000 USD (whichever is greater) (see Royalty Agreement and Subsequent Events below).

Management Fees

For the three months ended September 30, 2020, the Company recorded management fees of Nil compared to management fees of Nil for the same three month period ended September 30, 2019.

For the nine months ended September 30, 2020, the Company recorded management fees of Nil compared to management fees of $156,582 for the same nine month period ended September 30, 2019. The decrease in management fees during fiscal 2020, was a result of the reclassification of the salaries of the Company's Chief Executive Officer and its Chief Financial Officer to salaries and wages. During the first quarter of fiscal 2019, management fees included executive salaries, corporate overhead and royalty expense that were charged by the Company's US parent, MEDD.

Finance Costs

For the three months ended September 30, 2020, the Company recorded finance costs of $16,903 lower by $5,285 compared to finance costs of $22,188 for the three months ended September 30, 2019. During the three month period in 2020, the Company recorded interest payable of $7,980 to iCapital (September 30, 2019: $9,638), interest on right of use assets of $4,089 (September 30, 2019: $3,666), interest payable to radiologists of $3,076 (September 30, 2019: $7,035) and accrued interest of $1,520 a loan payable to the Chief Executive Officer of the Company (September 30, 20419: $1,520).

For the nine months ended September 30, 2020, the Company recorded finance costs of $50,061, which was lower by $16,601 compared to finance costs of $66,662 for the nine months ended September 30, 2019. During the nine months in 2020, the Company recorded interest payable of $20,252 to iCapital (September 30, 2019: $28,571), interest on right of use assets of $13,277 (September 30, 2019: $6,817), interest payable to radiologists of $11,309 (September 30, 2019: $23,750), and accrued interest of $4,559 on a loan payable to the Chief Executive Officer of the Company (September 30, 2019: $6,796).

General and Administrative

General and administrative costs totaled $26,396 for the three months ended September 30, 2020, which was higher by $17,871 compared to general and administrative costs of $8,525 for the three month period ended September 30, 2019. The higher general and administrative costs experienced in fiscal 2020, was primarily related to an increase of $9,562 to $18,537 in computer services and technical support versus $8,975 for the same three month period ended September 30, 2019 and higher postage and delivery costs of $2,198 compared to $56 for the same period in fiscal 2019.

General and administrative costs for the nine months ended September 30, 2020, were $66,003 compared to general and administrative costs of $32,669 for the nine month period ended September 30, 2019. The higher general and administrative costs recorded in fiscal 2020 was primarily attributed an increase of $22,238 to $38,808 in computer services and technical support versus $16,570 for the same nine month period ended September 30, 2019 and higher postage and delivery costs of $6,044 compared to $880 for the same period in fiscal 2019

Professional Fees

For the three months ended September 30, 2020, the Company recorded professional fees of $53,258 up by $50,219 compared to $3,039 for the three months ended September 30, 2019.

For the nine months ended September 30, 2020, the Company recorded professional fees of $137,026 an increase of $133,537 compared to $3,489 for the three months ended September 30, 2019.

The increase in professional fees for the three and nine month periods ended September 30, 2020, was primarily attributed to the Company's ongoing continuous disclosure requirements with respect to the business combination with Leveljump Healthcare Corp., and a Securities Exchange Agreement entered into with FogChain which was subsequently terminated.

Depreciation and Amortization

For the three months ended September 30, 2020, depreciation and amortization costs were $8,183 versus $13,476 for the same three month period ended September 30, 2019.

For the nine months ended September 30, 2020, depreciation and amortization costs were $24,548 versus $48,051 for the same nine month period ended September 30, 2019.

The decrease in depreciation and amortization costs for the current three and nine month periods in fiscal 2020 was primarily attributed to a decrease in the Company's office and computer lease assets. During the 4th quarter of fiscal 2019, the Company impaired its computer equipment in the amount of $14,277.

Insurance
Insurance expense for the three months ended September 30, 2020, was $7,217 which remained relatively consistent compared to insurance expense of $7,532 for the comparable three month period in 2019.

Insurance expense for the nine months ended September 30, 2020, was down slightly to $15,086 compared to insurance expense of $15,810 for the comparable nine month period in 2019.

The decrease experienced during the three and nine month period in fiscal 2020 was related to a decrease in liability insurance coverage.

Premises Rental
For the three months ended September 30, 2020, the Company incurred premises rental costs of $2,703 compared to premises rental costs of $7,430 for the three months ended September 30, 2019.

For the nine months ended September 30, 2020, the Company incurred premises rental costs of $7,804 compared to premises rental costs of $22,446 for the nine months ended September 30, 2019.

The decrease in premises rental costs during the current three and nine month periods in fiscal 2020 was attributed to a reduction in rent costs after the Company relocated its office.

Foreign Exchange Loss
For the three months ended September 30, 2020, the Company recorded a foreign exchange loss in the amount of $974 versus a foreign exchange loss of $381 for the same three month period in 2019.

For the nine months ended September 30, 2020, the Company recorded a foreign exchange loss in the amount of $2,336 versus a foreign exchange loss of $381 for the same nine month period in 2019.

Expenses recorded in the non-functional currency of the Company are translated at the rate of exchange in effect at the date of the transactions. Foreign exchange translation gains and losses are recorded in operations in the period in which they occur.

Travel and Entertainment
Travel and entertainments costs were $2,000 for the three months ended September 30, 2020, compared to travel and entertainments costs of $1,570 recorded during the three months ended September 30, 2019.

Travel and entertainments costs were up slightly to $2,694 for the nine months ended September 30, 2020, compared to travel and entertainments costs of $2,353 recorded during the nine months ended September 30, 2019.

Marketing
For the three months ended September 30, 2020, the Company recorded marketing costs of Nil compared to marketing costs of Nil for the same three month period in 2019.

For the nine months ended September 30, 2020, the Company recorded marketing costs of $385 compared to marketing costs of $196 for the same nine month period in 2019.

TOTAL EXPENSES

Total expenses for the three months ended September 30, 2020, were $244,057, higher by $54,24 when compared to total expenses of $189,833 for the three months ended September 30, 2019. The primary factors relating to the increase in total expenses during the three month period in 2020 were an increase in professional fees of $50,219, and an increase of $17,871 in general and administrative. These increases experienced in the 2020, were partially offset by a decrease of $5,293 in amortization and depreciation and a decrease of $5,285 in finance costs.

Total expenses for the nine months ended September 30, 2020, were $679,479, higher by $70,159 when compared to total expenses of $609,320 for the nine months ended September 30, 2019. The primary factors relating to the increase in total expenses during the nine month period in 2020 were an increase in professional fees of $133,537, an increase in salaries and wages of $80,594, an increase of $33,334 in general and administrative costs and an increase of $32,261 in royalty costs. These increases experienced in the current period in 2020 were partially offset by a decrease in management fees of $156,582, a decrease in depreciation and amortization of $23,503 and a decrease of $16,601 in finance costs.

NET INCOME AND COMPREHENSIVE INCOME

As a result of the above factors, the Company recorded net income and comprehensive income for the three months ended September 30, 2020, of $42,151 down by $31,960 compared to a net income and comprehensive income of $74,111 for the three months ended September 30, 2019.

For the nine month period ended September 30, 2020, the Company recorded net income and comprehensive of $122,194 down $33,997 compared to a net income and comprehensive income of $156,191 for the nine months ended September 30, 2019.

NET INCOME AND COMPREHENSIVE INCOME PER SHARE – BASIC AND DILUTED

The net income and comprehensive income per share-basic and diluted for the three months ended September 30, 2020, was $263 versus income per share-basic and diluted of $666 for the comparable three month period in 2019.

The net income and comprehensive income per share-basic and diluted for the nine months ended September 30, 2020, was $764 versus income per share-basic and diluted of $976 for the comparable nine month period in 2019.

SUMMARY OF QUARTERLY RESULTS

The following tables reflect the summary of quarterly results for the periods set out:

Quarter Ended	September 30, 2020	June 30, 2020	March 31, 2020	December 31, 2019
Total revenue	1,518,375	1,214,162	1,283,865	1,449,239
Gross margin	286,208	263,857	251,608	271,254
Expenses	244,057	234,954	202,541	321,471
Net income (loss)	42,151	28,902	49,068	(50,217)
Income (loss) per share–basic and diluted	263	181	306	(314)

During the quarter ended September 30, 2020, the increase in revenue was due to an increase in patient volume at hospitals and clinics.

For the quarter ending June 30, 2020 and March 31, 2020, revenue was down due to a reduction in patient volume at hospitals primarily as a result COVID-19. Revenue over the September and December 2019 quarters grew steadily, as demand for the Company's teleradiology services increased. Admin and sublease revenue remained relatively consistent throughout the four quarters.

For the quarter ending June 30, 2020 and March 31, 2020 gross margin was down due to a decline in patient volume. For the quarter ending December 31, 2019 gross margin increased as result of increased revenue which was partially offset by the gradual higher cost of sales including readings fees.

Expenses over the quarters fluctuated primarily due to changes in salaries and wages, finance costs, premises rental costs, professional fees, insurance and general and administrative costs. During the quarter ended December 31, 2019, the Company experienced higher costs related to audit fees.

Quarter Ended	September 30, 2019	June 30, 2019	March 31, 2019	December 31, 2018
Total revenue	1,371,537	1,437,439	1,114,604	1,176,387
Gross margin	263,944	295,712	205,855	232,676
Expenses	189,833	172,035	247,451	258,139
Net income (loss)	74,111	123,677	(41,596)	(25,463)
Income (loss) per share–basic and diluted	666	1,237	(416)	(255)

Revenue over the four quarters during continued to grow, as demand for the Company's teleradiology services increased. Admin and sublease revenue continually decreased over the four quarters. During the quarter ending September 30, 2019, the Company incurred a decrease in teleradiology revenue due to a reduction in patient volume.

Gross margin over the four quarters fluctuated as result of increased or decreased revenue due to changes in patient volume, as well as changes in cost of sales including readings fees, medical images archiving, internet connectivity and radiologists and medical director expenses. For the quarter ending September 30, 2019, gross margin was down due to a decline in patient volume.

Expenses over the four quarters fluctuated primarily due to changes in finance costs, premises rental, professional fees, insurance and salaries and wages. During the three month period ended March 31, 2019, the Company incurred management fees of $156,582.

OFF-BALANCE SHEET ARRANGEMENTS

The Company did not enter into any off-balance sheet arrangements as of the date of this MD&A.

OPERATING SEGMENTS

The Company's business activities comprise a single operating segment. In addition, the Company operates in a single geographical segment, Ontario Canada. The Company's revenues are derived entirely from service rendered in Canada.

CAPITAL EXPENDITURES

For the nine months ended September 30, 2020, the Company did not have any capital expenditures. During the year ended December 31, 2019, the Company wrote off its property and equipment in the amount of $14,277.

The Company anticipates that its capital expenditures will increase in future reporting periods as the Company seeks to expand its operations and look to further opportunities of merit.

FINANCING ACTIVITIES

For the nine months ended September 30, 2020, the Company received loan proceeds of $40,000 from the Canadian Emergency Response Account ("CEBA") (December 31, 2019: Nil), a loan from Leveljump Healthcare Corp., of $25,000 (December 31, 2019: Nil), advances from a director of NIL (December 31, 2019: $24,600) and proceeds from long term debt of Nil (December 31, 2019: $80,000).

For the nine months ended September 30, 2020, the Company recorded advances to parent company of $90,168 (December 31, 2019: 159,264), re-paid long term debt in the amount of $48,452 (December 31, 2019: $72,266), repaid advances from directors of $13,435 (December 31, 2019: Nil) and recorded lease payments of $19,679 (December 31, 2019: $45,776).

LIQUIDITY AND CAPITAL RESOURCES

During the nine month period ended September 30, 2020, the Company's primary use of funds was related to administrative expenses. At September 30, 2020, the Company had a working capital deficiency of $720,924 compared to working capital deficiency of $741,604 at December 31, 2019.

The Company's current assets as at September 30, 2020, were $654,055 (December 31, 2019: $622,010) which consisted of cash in the amount of $10,357 (December 31, 2019: Nil), accounts receivable in the amount of $550,696 (December 31, 2019: $515,919), due from parent company $40,269 (December 31, 2019: $92,496), HST receivable of $29,730 (December 31, 2019: $6,145) and prepaid expenses and deposits totalling $23,003 (December 31, 2019: $7,450).

Current liabilities as at September 30, 2020, were $1,374,979 (December 31, 2019: $1,363,614) which were comprised of bank overdraft in the amount of Nil (December 31, 2019: $2,103), accounts payables and accrued liabilities of $1,217,241 (December 31, 2019: $1,170,874), current portion of lease liabilities $31,540 (December 31, 2019: $27,552), due to director $50,655 (December 31, 2019: $64,090), loan payable $25,000 (December 31, 2019: Nil), and current portion of long term debt in the amount of $50,543 (December 31, 2019: $98,995).

The continuing operations of the Company are dependent upon its ability to raise adequate financing and to continue its profitable operations in the future. Despite the Company generating comprehensive income of $122,194 during the nine months ended September 30, 2020, several adverse conditions cast significant doubt on the validity of the going concern assumption. Notably at September 30, 2020 the Company's accumulated deficit was $727,339 (December 31, 2019: $849,533) and its working capital deficiency was $720,924 (December 31, 2019: $741,064). These conditions indicate that material uncertainties exist that cast significant doubt on the Company's ability to continue as a going concern. The Company's ability to continue as a going concern is dependent upon raising additional capital to meet its present and future commitments and on achieving profitable commercial operations.

Although the Company has been successful in borrowing funds in the past, there can be no assurance that the Company will have sufficient financing to meet its future capital requirements or that additional financing will be available on terms acceptable to the Company in the future. The Company has and may continue to have capital requirements in excess of its currently available resources.

SIGNIFICANT ACCOUNTING POLICIES

Significant accounting estimates and judgments

The preparation of financial statements in conformity with IFRS requires management to make significant judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and related footnote disclosures. Use of available information and the application of judgment are inherent in the formation of estimates. Actual results in the future can differ from these estimates, which may be material to future financial statements.

Significant estimates and underlying assumptions are reviewed on a periodic basis. Management uses historical experience and various other factors it believes to be reasonable under the circumstances as the basis for its judgments and estimates. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements, are outlined below:

a. Trade receivables valuation – recoverability of receivables through the provision for doubtful accounts;
b. Depreciation of property and equipment – judgement is required in estimating the useful lives of property and equipment
c. Recoverability of deferred income tax assets – assessing whether the realization of tax losses against future taxable income for income tax purposes if probable.
d. Non-current asset impairment – assessing whether indicators of impairment exist at reporting year's end.

New Accounting Pronouncements

IAS 1 – Presentation of Financial Statements (“IAS 1”) and IAS 8 – Accounting Policies, Changes in Accounting Estimates and Errors (“IAS 8”) were amended in October 2018 to refine the definition of materiality and clarify its characteristics. The revised definition focuses on the idea that information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements. The amendments are effective for annual reporting periods beginning on or after January 1, 2020. There was no impact on the Company’s interim financial statements.

Business Combinations (“IFRS 3”) - In October 2018, the IASB issued an amendment to IFRS 3, effective for annual periods beginning on or after January 1, 2020 with early adoption permitted. The amendment clarifies that a business must include, at minimum, an input and a substantive process that together contribute to the ability to create outputs, and assists companies in determining whether an acquisition is a business combination or an acquisition of a group of assets by providing supplemental guidance for assessing whether an acquired process is substantive. The Company has decided to early adopt the amendments to IFRS 3 effective January 1, 2019 and shall apply the amended standard in assessing business combinations on a prospective basis. For acquisitions that are determined to be acquisitions of assets as opposed to business combinations, the Company allocates the transaction price to the individual identifiable assets acquired and liabilities assumed on the basis of their relative fair values, and no goodwill is recognized. Acquisitions that continue to meet the definition of a business combination are accounted for under the acquisition method, without any changes to the Company’s accounting policy. There was no impact on the Company’s interim financial statements

ROYALTY AGREEMENT

On October 1, 2018, CTS became party to the Amended and Restated Secured Royalty Purchase Agreement (the “Agreement”) between CTS’ parent company, MIC, and Flow Capital Corp (“Flow”). The terms impacting CTS were as follows:

- Effective October 1, 2018, CTS will pay a gross sales royalty based on of 2.5% of its revenues or $6,000 USD (whichever is greater) monthly to Flow.
- There was a cross-guarantee such that CTS will guarantee all royalty payments of MIC and vice-versa. Note that MIC is subject to the same gross sales royalty provisions as CTS; however, MIC is currently dormant and accordingly not generating any revenues giving rise to a royalty obligation.
- The Agreement will terminate on cumulative royalty payments to Flow reaching $4M USD.
- CTS may buyout the royalty obligation with a payment of $2M USD to Flow.
- Agreement secured by a general security agreement covering all of the CTS’ current and future assets.

On April 23, 2020, the Company agreed with Flow capital to defer 50% of its royalty payments due in April, May, and June to the 4th quarter of 2020.

On July 17, 2020, the Company and Flow entered into a Royalty Buyout Agreement (see Subsequent Events Note below).

LONG TERM DEBT

The following table sets out the changes in the Company’s long term debt for the periods set out:

Balance, January 1, 2019	$ 95,834
Proceeds from iCapital	80,000
Debt repayments	(76,839)
Balance, December 31, 2019	98,995
Proceeds from CEBA	40,000
Debt repayments	(48,452)
Balance, September 30, 2020	**$90,543**

The following table sets out the balance of the Company's long term debt for the periods set out:

	September 30, 2020	December 31, 2019
iCapital Financial Services Corp.	$50,543	$98,995
TD Canada Trust - CEBA	$40,000	-
TOTAL	**$90,543**	$98,995

iCapital Financial Services Corp. ("iCapital")
The Company has a term loan from iCapital that was originally issued on December 5, 2018, for the principal amount of $100,000 with a total repayment amount of $143,000. The loan had daily payments of $397 and matured in June 2020. There was a 3% initiation fee on the principal amount.

On May 8, 2019, the Company borrowed an additional $80,000 from iCapital, with a total cost of borrowing of $114,400, and the daily payments were adjusted to $600 per day. On September 12, 2019, the daily payments were reduced to $300 per day until January 10, 2020. The Company was paying $1,250 a week until June 30, 2020, at which time the payments changed to $1,800 a week. The loan matured in November 2020 and was paid in full subsequent to the period end (see Subsequent Events Note below).

The iCapital loan was secured by a general security agreement covering all the Company's current and future assets, additionally the CEO of the Company has executed a personal guarantee on the loan.

For the nine months ended September 30, 2020, the Company incurred interest on the loan of $20,252 (September 30, 2019: $28,571).

Canadian Emergency Response Account ("CEBA")
On April 17, 2020, the Company received $40,000 from the CEBA through TD Canada Trust. The loan is non-interest bearing until December 31, 2022, at which time if paid back in full, $10,000 is forgivable, and if not, the loan becomes a 3 year interest bearing term loan.

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Trade and other payables are principally comprised of amounts outstanding for subcontracted radiologists and for amounts relating to operating activities. The following table comprises accounts payable and accrued liabilities for the periods set out:

	September 30, 2020	December 31, 2019
Accounts payable	**$ 1,095,650**	$1,042,209
Accrued liabilities	**121,591**	128,665
	$ 1,217,241	$1,170,874

The standard maturity terms of the Company's trade and other payables are 30 to 60 days.

Included in accrued liabilities, $91,785 and $15,201 representing the accrued salary for the Company's CEO and CFO respectively, and $14,605 representing expenses paid by the Company's CFO on behalf of CTS.

LEASE LIABILITIES

The Company leases end in July and August 2022. The aggregate lease payment is $3,732/monthly. The changes in the Company's lease liabilities is presented in the table below for the periods set out:

Balance, January 1, 2019	$ -
Additions	123,659
Lease payments	(35,410)
Balance, December 31, 2019	88,249
Lease payments	(19,679)
Balance, September 30, 2020	**$68,570**

The following table presents the balance of the Company's lease liabilities for the periods set out:

	September 30, 2020	December 31, 2019
Current portion	$31,540	$27,552
Long term portion	37,030	60,697
Balance, September 30, 2020	**$68,570**	$88,249

$3,077 of the company's lease liability was deferred until the fourth quarter of 2020.

SHARE CAPITAL AND RESERVES

Authorized:
Unlimited number of common shares

Issued:
(1) On June 30, 2019, the Company issued 33 shares of Class A common shares to its CEO/Director in exchange for $50,000 of money previously loaned to the Company.

(2) On September 30, 2019, the Company issued 27 Class A common shares to its CFO/Director in exchange for settling a $15,000 loan and for $26,000 of past due salary.

At September 30 30, 2020 and 2019 the Company did not have any potential dilutive instruments.

RELATED PARTY TRANSACTIONS AND BALANCES

During the periods ended September 30, 2020 and 2019 the Company maintained various transactions with related parties. The related parties consist of officers, directors and shareholders or companies controlled directly or indirectly by them. Details of the related parties including transactions and balances owing, or receivable, are as follows:

Related Party	**Nature of Relationship**
Mitchell Geisler	CEO, President and Director
Robert Landau	CFO and Director
MEDD Medical Imaging Corp. ("MIC")	CTS' US Parent Company

Related Party Transactions
Mitchell Geisler loaned the Company $100,655 as of June 29th, 2018. The amount is represented by a promissory note and is due on June 30, 2022. Interest on the note is 10%. The promissory note is secured by any and all of the Company's assets. The Company can and has made early payments towards the principal amount of the loan. On June 30, 2019, Mr. Geisler converted $50,000 of the loan into common shares of the Company.

As at September 30, 2020, the balance of the loan was $50,655 in principal and $17,994 in accrued interest which is included in accounts payable and accrued liabilities (December 31, 2019: $50,655 principal and $13,435 interest) (September 30, 2019: $50,655 principal and $11,916 interest).

On September 24, 2019, the Company borrowed $15,000 from Robert Landau with no set terms of repayment or interest. On September 30, 2019, the Company issued 27 Class A common shares to Robert Landau in exchange for settlement of the $15,000 loan and $26,500 of past due salary. At September 30, 2020, the outstanding amount due to Robert Landau of $14,605 for expenses paid on behalf of CTS was included in accounts payable and accrued liabilities (December 31, 2019: $9,605).

During the nine-month period ended September 30, 2020, CTS paid MEDD Medical Imaging Corp ("MIC") management fees, for executive salaries and certain corporate overhead, of Nil (September 30, 2019 - $156,582).

During the period ended September 30, 2020, CTS advanced $90,168 to MIC. On June 9, 2020, CTS converted $142,395 of its loan receivable from MIC into common shares of MIC (see Investment Note 4 and Note 12 Subsequent Events). The amounts due from MIC are non-interest bearing and due on demand.

Key Management Compensation

The Company defines key management as its CEO, CFO and Directors. Key management compensation for the three and nine months ended September 30, 2020 was $84,000 and $252,000 respectively (September 30, 2019: $72,000 and $120,000, respectively).

For the three and nine month periods ended September 30, 2020, the Company recorded salary of $42,000 and $126,000, respectively to Mitch Geisler. (September 30, 2019: $36,000 and 60,000, respectively). At September 30, 2020, included in accounts payable and accrued liabilities is $91,875 of accrued salary (December 31, 2019: $8,315) (September 30, 2019: $32,000).

For the three and nine month periods ended September 30, 2020, the Company recorded salary of $42,000 and $126,000, respectively to Robert Landau. (September 30, 2019: $36,000 and 60,000, respectively). At September 30, 2020, included in accounts payable and accrued liabilities is $15,201 of accrued salary (December 31, 2019: Nil) (September 30, 2019: Nil).

SUBSEQUENT EVENTS

On November 2, 2020, the Company entered into a share purchase agreement with Mitchell Geisler, the President of the Company to sell 39,491,111 of its common shares held in MEDD for proceeds of $68,787. The transaction is expected to close on or before December 31, 2020.

On November 2, 2020, the Company entered into a share purchase agreement with Robert Landau, the Chief Financial Officer of the Company to sell 39,491,111 of its common shares held in MEDD for proceeds of $68,787. The transaction is expected to close on or before December 31, 2020.

On December 7, 2020, the Company and Good2Go2 Corp. a Capital Pool Corporation (“Good2Go2”) closed its business combination as the "Qualifying Transaction" of Good2Go2 (as such term is defined within the meaning of Policy 2.4 - Capital Pool Companies of the TSX Venture Exchange (the "Exchange")). In connection with the Business Combination Agreement, Good2Go2 advanced $25,000 on an unsecured basis to CTS.

Pursuant to the terms of the Business Combination Agreement dated effective July 15, 2020 and subsequent amending agreements entered among the Company, Good2Go2 and 12199483 Canada Inc. ("Subco"), a wholly-owned subsidiary of Good2Go2, CTS and Subco amalgamated under the *Canada Business Corporations Act* on December 7, 2020. Immediately prior to the closing of the Qualifying Transaction, Good2Go2 consolidated its common shares on a 1.8-for-one basis (the "Consolidation") resulting in 3,027,778 post-Consolidation shares and changed its name to Leveljump Healthcare Corp.

An aggregate of 27,275,000 post-Consolidation shares of Leveljump Healthcare Corp. were issued to the holders of Common shares of CTS and placed in escrow pursuant to a value security escrow agreement pursuant to the policies of the Exchange and will be released in accordance with the terms thereof.

Prior to closing the Qualifying Transaction, CTS completed a two-tranche brokered private placement pursuant to which an aggregate of 10,061,622 subscription receipts of CTS ("Subscription Receipts") were issued (the "Subscription Receipt Financing") as follows: (i) 8,700,511 Subscription Receipts for aggregate cash gross proceeds of $3,915,230; (ii) 1,111,111 Subscription Receipts to Flow Capital Corp. at a deemed value of $500,000 as part of a Royalty Buy-Out; and (iii) 250,000 Subscription Receipts as payment for a work fee and advisory fee.

On July 17, 2020, in connection with the Transaction, CTS and its principal shareholder, MEDD Medical Imaging Corp., entered into a Royalty Buyout Agreement with Flow Capital as amended by Buyout Amending Agreements dated October 28, 2020 and November 24, 2020 respectively. The Flow Capital Royalty Buyout was completed prior to the Listing Date as follows:

(i) C$1,500,000 in cash;
(ii) 1,111,111 Subscription Receipts (which have been issued along with the First Tranche Closing) at a deemed value of $500,000; and
(iii) 3,288,889 Resulting Issuer Shares, as a result of the Resulting Issuer Share allotment to be received by MEDD Medical Imaging Corp. in connection with the Transaction.

The common shares of Leveljump Healthcare Corp. resumed trading on the Exchange as a Tier 1 technology issuer on December 14, 2020 (the “Listing Date”) under the new name "Leveljump Healthcare Corp.", with the trading symbol "JUMP".

Subsequent to the period ended September 30, 2020, the Company paid the iCapital term loan and interest in full in the amount of $46,154.80

On October 28, 2020, Flow Capital and each of Mitchell Geisler, Robert Landau and MEDD Medical Imaging Corp. entered into a Priority and Swap Agreement such that Geisler, Landau and MEDD will provide Flow Capital with all or most of their allotment of escrow released JUMP shares 180 days following the closing of the Qualifying Transaction in exchange for restricted JUMP shares held by Flow Capital, as an inducement for Flow to agree to the amended buyout of the Royalty and allow the QT to close. The Company has agreed to reimburse each of Geisler and Landau the sum of $133,818 in exchange for the option on their shares as well as their tax burden on the share exchange. The Company has agreed to reimburse MEDD the sum of $76,601 in exchange for the option on their shares as well as their tax burden on the share exchange.